A higher proportion of drug-naive type 2 diabetes patients achieved blood glucose levels lower than 7% with once-daily lixisenatide for 12 weeks compared with those who received placebo treatment, researchers reported in Diabetes Care. Lixisenatide-treated patients also had bigger drops in two-hour postprandial glucose levels than those in the placebo group, researchers noted.
Lixisenatide shows efficacy in type 2 diabetes management
SmartBrief Job Listings for Health Care
|Vice President of Regulatory Affairs||
|Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX||
|Santa Clara, CA|
|Senior Director, Biostatistics||